MX2018015414A - Terapia de célula t adoptiva mejorada. - Google Patents

Terapia de célula t adoptiva mejorada.

Info

Publication number
MX2018015414A
MX2018015414A MX2018015414A MX2018015414A MX2018015414A MX 2018015414 A MX2018015414 A MX 2018015414A MX 2018015414 A MX2018015414 A MX 2018015414A MX 2018015414 A MX2018015414 A MX 2018015414A MX 2018015414 A MX2018015414 A MX 2018015414A
Authority
MX
Mexico
Prior art keywords
trivalent
bispecific antibody
cells
antibody molecules
present
Prior art date
Application number
MX2018015414A
Other languages
English (en)
Inventor
Niederfellner Gerhard
Sustmann Claudio
Klein Christian
Geiger Martina
Endres Stefan
Kobold Sebastian
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2018015414A publication Critical patent/MX2018015414A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A61K39/464403—Receptors for growth factors
    • A61K39/464404—Epidermal growth factor receptors [EGFR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464466—Adhesion molecules, e.g. NRCAM, EpCAM or cadherins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464466—Adhesion molecules, e.g. NRCAM, EpCAM or cadherins
    • A61K39/464468—Mesothelin [MSLN]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3053—Skin, nerves, brain
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Abstract

La presente invención se refiere generalmente a células T, tal como células T CD8+, células T CD4+, células T CD3+, células T ?d o células T asesinas por naturaleza (NK), transfectadas/transducid as con una proteína de fusión que se incorpora por el uso de molécula de anticuerpo trivalente, biespecífico que se une a/interactúa específicamente con el dominio extracelular de la proteína de fusión. Más precisamente, la presente invención se refiere a un kit que comprende las moléculas de ácido nucleico, vectores y/o las proteínas de fusión de la presente invención y las moléculas de anticuerpo trivalente, biespecífico de la presente invención. Aspectos adicionales de las invenciones son los vectores de expresión que comprenden las moléculas de ácido nucleico que codifican las proteínas de fusión así como las moléculas de anticuerpo trivalente, biespecífico. Además, se describe un proceso para la producción de las moléculas de anticuerpo trivalente, biespecífico de la invención y una composición de medicamento/farmacéutica que comprende dichas moléculas de anticuerpo trivalente, biespecífico. La invención también proporciona el uso de dichas moléculas de anticuerpo trivalente, biespecífico en un método para el tratamiento de enfermedades particulares así como una composición farmacéutica/medicamento que comprende dichas moléculas de anticuerpo trivalente, biespecífico, en donde dicha(s) molécula(s) de anticuerpo trivalente, biespecífico ha(n) de administrarse en combinación con células T transducidas que comprenden la proteína de fusión de la invención. La invención también proporciona un método para el tratamiento de enfermedades particulares.
MX2018015414A 2016-06-30 2017-06-30 Terapia de célula t adoptiva mejorada. MX2018015414A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16177203 2016-06-30
PCT/EP2017/066375 WO2018002358A1 (en) 2016-06-30 2017-06-30 Improved adoptive t-cell therapy

Publications (1)

Publication Number Publication Date
MX2018015414A true MX2018015414A (es) 2019-08-01

Family

ID=56296678

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018015414A MX2018015414A (es) 2016-06-30 2017-06-30 Terapia de célula t adoptiva mejorada.

Country Status (11)

Country Link
US (1) US11547748B2 (es)
EP (1) EP3478722A1 (es)
JP (2) JP7175769B2 (es)
KR (1) KR20190025855A (es)
CN (1) CN109476749A (es)
AU (1) AU2017291262A1 (es)
BR (1) BR112018077375A2 (es)
CA (1) CA3026858A1 (es)
IL (1) IL263513A (es)
MX (1) MX2018015414A (es)
WO (1) WO2018002358A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013113615A1 (en) * 2012-02-03 2013-08-08 F. Hoffmann-La Roche Ag Bispecific antibody molecules with antigen-transfected t-cells and their use in medicine
US11535662B2 (en) * 2017-01-26 2022-12-27 Novartis Ag CD28 compositions and methods for chimeric antigen receptor therapy
WO2019057100A1 (en) 2017-09-21 2019-03-28 Wuxi Biologics (Shanghai) Co., Ltd. NEW ANTI-CD19 ANTIBODIES
JP2022537333A (ja) * 2019-06-19 2022-08-25 エフ．ホフマン－ラ ロシュ アーゲー 所定の構成の複数の発現カセットの標的化組込みによって多価の多重特異性抗体発現細胞を作製するための方法
GB201911066D0 (en) 2019-08-02 2019-09-18 Achilles Therapeutics Ltd T cell therapy
US11723926B2 (en) 2019-09-27 2023-08-15 Starkage Therapeutics Senescent cell-associated antigen-binding domains, antibodies and chimeric antigen receptors comprising the same, and uses thereof
GB201915384D0 (en) * 2019-10-23 2019-12-04 Ucl Business Ltd Vector
EP4106819A1 (en) 2020-02-21 2022-12-28 Silverback Therapeutics, Inc. Nectin-4 antibody conjugates and uses thereof
CA3176654A1 (en) 2020-04-28 2021-11-04 Karl PEGGS T cell therapy
KR20230047361A (ko) 2020-07-01 2023-04-07 아르스 파마슈티컬스 인크. 항-asgr1 항체 접합체 및 이의 용도
US20230322898A1 (en) 2020-07-31 2023-10-12 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition comprising cell expressing chimeric receptor
US11661459B2 (en) 2020-12-03 2023-05-30 Century Therapeutics, Inc. Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
CN116981685A (zh) * 2020-12-03 2023-10-31 世纪治疗股份有限公司 基因工程化细胞及其用途
GB202109886D0 (en) 2021-07-08 2021-08-25 Achilles Therapeutics Uk Ltd Assay
EP4320435A1 (en) 2021-04-09 2024-02-14 Achilles Therapeutics UK Limited Batch release assay for pharmaceutical products relating to t cell therapies
WO2022269250A1 (en) 2021-06-22 2022-12-29 Achilles Therapeutics Uk Limited A method for producing antigen-specific t cells

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
GB9304200D0 (en) 1993-03-02 1993-04-21 Sandoz Ltd Improvements in or relating to organic compounds
DE69434447T2 (de) 1993-06-07 2006-05-18 Vical, Inc., San Diego Für die gentherapie verwendbare plasmide
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
CA2225460A1 (en) 1995-06-23 1997-01-09 Winston Campbell Patterson Transcriptional regulation of genes encoding vascular endothelial growth factor receptors
DE19822115B4 (de) 1998-05-08 2004-04-08 Heinrich-Pette-Institut Retrovirale Gentransfervektoren
AU2002226930A1 (en) * 2000-11-17 2002-05-27 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Reduction of the nonspecific animal toxicity of immunotoxins by mutating the framework regions of the fv to lower the isoelectric point
AU2004242846A1 (en) * 2003-05-31 2004-12-09 Micromet Ag Pharmaceutical compositions comprising bispecific anti-CD3, anti-CD19 antibody constructs for the treatment of B-cell related disorders
EP1692182B1 (en) * 2003-11-05 2010-04-07 Roche Glycart AG Cd20 antibodies with increased fc receptor binding affinity and effector function
EP1930433B1 (en) 2005-09-13 2016-03-16 Mie University T-cell receptor and nucleic acid encoding the receptor
US20110280894A1 (en) 2008-07-31 2011-11-17 Angela Krackhardt Her2/neu specific t cell receptors
CN102164961B (zh) * 2008-10-01 2014-04-16 安进研发（慕尼黑）股份有限公司 种间特异性PSCAxCD3、CD19xCD3、C-METxCD3、内皮唾液酸蛋白xCD3、EpCAMxCD3、IGF-1RxCD3或FAPαxCD3双特异性单链抗体
JP5616428B2 (ja) 2009-04-07 2014-10-29 ロシュ グリクアート アクチェンゲゼルシャフト 三価の二重特異性抗体
PT2496698T (pt) * 2009-11-03 2019-04-18 Hope City Recetor de fator de crescimento epidermal truncado (egfrt) para seleção de células t transduzidas
NZ612512A (en) 2010-12-09 2015-03-27 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
PT3459560T (pt) 2011-04-08 2021-05-24 Us Health Recetores de antigénio quimérico variante iii de recetor de fator de crescimento antiepidérmico e utilização dos mesmos para o tratamento de cancro
PL2748201T3 (pl) 2011-08-23 2018-04-30 Roche Glycart Ag Aktywujące komórki t dwuswoiste cząsteczki wiążące antygen
CA2851795C (en) 2011-10-20 2018-11-13 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-cd22 chimeric antigen receptors
WO2013113615A1 (en) * 2012-02-03 2013-08-08 F. Hoffmann-La Roche Ag Bispecific antibody molecules with antigen-transfected t-cells and their use in medicine
EP2828290B1 (en) 2012-03-23 2018-08-15 The United States of America, represented by the Secretary, Department of Health and Human Services Anti-mesothelin chimeric antigen receptors
EP3689383A1 (en) 2012-04-11 2020-08-05 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Chimeric antigen receptors targeting b-cell maturation antigen
HUE047925T2 (hu) * 2013-02-26 2020-05-28 Roche Glycart Ag Bispecifikus, T-sejt-aktiváló, CD3- és CEA-specifikus antigénkötõ molekulák
US9657105B2 (en) 2013-03-15 2017-05-23 City Of Hope CD123-specific chimeric antigen receptor redirected T cells and methods of their use
UY35468A (es) 2013-03-16 2014-10-31 Novartis Ag Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
WO2015028444A1 (en) 2013-08-26 2015-03-05 Universität Zu Köln Anti cd30 chimeric antigen receptor and its use
AU2014329437B2 (en) * 2013-10-06 2018-10-18 F. Hoffmann-La Roche Ag Modified Pseudomonas exotoxin A
CA2951599A1 (en) 2014-08-04 2016-02-11 F. Hoffmann-La Roche Ag Bispecific t cell activating antigen binding molecules
CN107429253B (zh) 2014-12-05 2021-11-05 希望之城公司 Cs1靶向性嵌合抗原受体修饰的t细胞
PT3310805T (pt) * 2015-06-19 2021-05-19 Kobold Sebastian Proteínas de fusão pd-1-cd28 e a sua utilização em medicina
CN108026179A (zh) * 2015-10-02 2018-05-11 豪夫迈·罗氏有限公司 结合间皮素和cd3的双特异性t细胞活化性抗原结合分子
PL3433280T3 (pl) * 2016-03-22 2023-07-31 F. Hoffmann-La Roche Ag Dwuswoiste cząsteczki limfocytów T aktywowane przez proteazy

Also Published As

Publication number Publication date
JP2022169543A (ja) 2022-11-09
KR20190025855A (ko) 2019-03-12
BR112018077375A2 (pt) 2019-10-01
CA3026858A1 (en) 2018-01-04
US20190216908A1 (en) 2019-07-18
EP3478722A1 (en) 2019-05-08
AU2017291262A1 (en) 2019-01-03
JP7175769B2 (ja) 2022-11-21
WO2018002358A1 (en) 2018-01-04
JP2019527680A (ja) 2019-10-03
IL263513A (en) 2019-01-31
CN109476749A (zh) 2019-03-15
US11547748B2 (en) 2023-01-10

Similar Documents

Publication Publication Date Title
MX2018015414A (es) Terapia de célula t adoptiva mejorada.
Schmohl et al. Heterodimeric bispecific single chain variable fragments (scFv) killer engagers (BiKEs) enhance NK-cell activity against CD133+ colorectal cancer cells
MX2018001567A (es) Novedosos polipeptidos de fusion especificos para lag-3 y pd-1.
PH12018501220A1 (en) Bispecific molecules having immunoreactivity with pd-1 and ctla-4, and methods of use thereof
SA518400424B1 (ar) جزيئات الجسم المضاد لعلاج السرطان
PE20200152A1 (es) Receptores de union a antigeno mejorados
MX2019006954A (es) Terapia de combinacion de anticuerpos biespecificos anti-cd20/anti-cd3 y agonistas de 4-1bb (cd137).
NZ739448A (en) Transgene genetic tags and methods of use
MX2020001198A (es) Agentes de union que se unen a ligando 1 de muerte programada (pd-l1) y grupo de diferenciacion 137 (cd137) y uso de los mismos.
IN2014MN01781A (es)
PH12017501583A1 (en) Novel proteins specific for cd137
MX2014008963A (es) Moleculas de anticuerpos biespecificos con celulas t transfectadas por antigeno y su uso en medicina.
EA201892021A1 (ru) Трансфицированные t-клетки и t-клеточные рецепторы для применения в иммунотерапии раковых заболеваний
AU2016277883A8 (en) PD-1-CD28 fusion proteins and their use in medicine
EA201891759A1 (ru) Трансфицированные t-клетки и t-клеточные рецепторы для применения в иммунотерапии раковых заболеваний
MX2019000586A (es) Virus adenoasociados (aav) sflt-1 para usarse en el tratamiento de degeneración macular relacionada con la edad (amd).
MX2020008075A (es) Anticuerpos anti-ctla4 y métodos para elaborarlos y usarlos.
EP4249064A3 (en) Novel fusion protein specific for cd137 and pd-l1
TR201900649T4 (tr) Oküler hastalıkların tedavisi için mrna tedavisi.
BR112013019975A2 (pt) proteínas de ligação de antígeno, composição farmacêutica, uso de uma proteína de ligação de antígeno, método para o tratamento de um paciente e método para a preparação de uma proteína de ligação de antígeno, ácido nucleico, vetor e célula hospedeira"
MX2021010039A (es) Novedosas proteinas de fusion especificas para cd137 y gpc3.
EA201892619A1 (ru) Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
EA201391761A1 (ru) Анти-альфа-синуклеинсвязывающие молекулы
MA49355A (fr) Formats de récepteurs de liaison d'antigène améliorés
PH12019501387A1 (en) Anti-cd3 antibody and molecules comprising the antibody